CRISPR Therapeutics AG - Common Shares (CRSP)

$44.51 0.00 (0.00%)

16:00 EST CRSP Stock Quote Delayed 30 Minutes

Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development

By John Blankenhorn, InvestorPlace Contributor Dec 15, 2023

These pharma stock leaders offer revolutionary treatments that could change the world of medicine (and investor's portfolios) for the better.

3 Small-Cap Stocks That Could Skyrocket 1000% by 2030

3 Gene-Editing Stocks With the Potential to Mint Millionaires

Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy

Volume:

Previous Close -

Market Cap 3.51B

PE Ratio -10.23

EPS -4.35

Volume (Avg. Vol.) 5,514

Day's Range -

52-Week Range $36.52 - $90.62

Dividend & Yield N/A (N/A)

CRSP Stock Predictions, Articles, and CRISPR Therapeutics AG - Common Shares News

3 Biotech Stocks That Could Be Multibaggers in the Making

By Muslim Farooque, InvestorPlace Contributor Nov 30, 2023

Uncover investment opportunities with biotech stocks representing firms developing critical breakthroughs in treatments.

Google’s Bard AI Says These 3 Stocks Will Rise 1,000%

By Omor Ibne Ehsan Nov 20, 2023

Google's Bard has been among the best stock pickers, and thinks these three stocks have quadruple-digit upside potential.

3 Cathie Wood You’ll Regret Not Buying Soon: November 2023

By Jeremy Flint, InvestorPlace Contributor Nov 16, 2023

Cathie Wood thinks we're out of the woods economically, and these stock picks in her portfolio stand to gain the most in coming months.

CRISPR Therapeutics (CRSP) Stock Jumps as U.K. Authorizes Gene Therapy

By Dana Blankenhorn, InvestorPlace Contributor Nov 16, 2023

CRSP stock is up on U.K. authorization for its gene therapy treatment for sickle cell anemia. CRISPR hopes for FDA authorization next spring.

Invest in the Future With These 7 Forever Stocks

By Jeremy Flint, InvestorPlace Contributor Nov 15, 2023

Forever stocks are usually those predicting future trends. Finding them today means pinning down strong financials and prospects without FOMO

3 Biotech Stocks With Key Catalysts Coming in December

By Ian Cooper, InvestorPlace Contributor Nov 15, 2023

Some of the most exciting opportunities can be found in biotech stocks, especially if there's a powerful catalyst just around the corner.

3 Biotech Stocks That Are Poised to Have Breakthroughs in 2024

By Larry Ramer, InvestorPlace Contributor Nov 12, 2023

Investors should consider these "Goldilocks" biotech stocks to buy as they are poised to get significant boosts next year.

3 Biotech Stocks That Are Betting on the Future of Gene Editing

By Chris Markoch, InvestorPlace Contributor Nov 9, 2023

These three companies have gene editing therapies in late-stage clinical trials, making them promising biotech stocks to buy right now.

3 Biotech Stocks With the Strongest Clinical Pipelines

By Ian Cooper, InvestorPlace Contributor Nov 8, 2023

Many industry heavyweights are on the hunt for fresh new ideas -- great news for biotech stocks to buy with strong pipelines.

7 Tech Stocks to Buy and Hold for the Next 25 Years

By Chris Markoch, InvestorPlace Contributor Nov 5, 2023

To find tech stocks to buy and hold for the next 25 years, you can look at some of the tech trends and the leaders in those areas

CRSP Stock Alert: Can CRISPR Therapeutics Short Squeeze Higher?

By Larry Ramer, InvestorPlace Contributor Nov 1, 2023

CRSP stock is rallying after an FDA panel appeared to view CRISPR Therapeutics' sickle-cell anemia treatment as safe.

CRSP Stock Halt: CRISPR Trading Halted Ahead of FDA Decision

By Chris MacDonald, InvestorPlace Contributor Oct 31, 2023

Investors in CRISPR and CRSP stock have certainly been on a wild ride so far this year. Here's what investors need to watch right now.

CRSP Stock: FDA Considers Additional Review of CRISPR Therapeutics Gene Therapy

By Josh Enomoto, InvestorPlace Contributor Oct 27, 2023

Although CRISPR Therapeutics may have a breakthrough drug on its hands, regulatory concerns hang over CRSP stock.

7 Biotech Stocks to Get In Now Before Investors Catch On

By John Blankenhorn, InvestorPlace Contributor Oct 23, 2023

Biotech stocks are down, but there are hidden gems among the rubble. Get in now before the broader market finds them.

3 Gene Editing Stocks to Generate Super-Charged Gains

By Ian Cooper, InvestorPlace Contributor Oct 18, 2023

As things progress, such techniques may be able to knock out every disease known, creating massive opportunity for gene-editing stocks.

Biotechnology Breakthroughs: 3 Biotech Stocks That Could Make Early Investors Rich

By Yiannis Zourmpanos, InvestorPlace Contributor Oct 3, 2023

Are you looking to invest in biotechnology breakthroughs? Here are three biotech stocks that could make early investors rich.

3 Cathie Wood Stocks Set to Explode Higher

By Muslim Farooque, InvestorPlace Contributor Oct 1, 2023

Delve into the exciting world of Cathie Wood Stocks where potential meets performance, offering investors hefty long-term upside.

Futurescape: Betting Big on These 3 Next-Gen Tech Stocks

By Yiannis Zourmpanos, InvestorPlace Contributor Oct 1, 2023

Amidst this ever-evolving landscape, three companies stand out as beacons of forward-thinking progress and visionary leadership.

Don’t Miss the Boom: 3 Pharma Stocks Set to Explode Higher

By Omor Ibne Ehsan Sep 27, 2023

These pharma stocks could boom in the coming years, riding their diversified pipelines with massive addressable markets higher.

From Dust to Diamonds: 7 Undervalued Stocks With Sparkling Prospects

By Yiannis Zourmpanos, InvestorPlace Contributor Sep 27, 2023

Like diamonds in the rough, these undervalued stocks possess the potential to shine brightly in an investment portfolio.

CRISPR Therapeutics AG - Common Shares (CRSP)

Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development

3 Small-Cap Stocks That Could Skyrocket 1000% by 2030

3 Gene-Editing Stocks With the Potential to Mint Millionaires

Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

CRISPR Therapeutics AG - Common Shares (CRSP)

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

CRSP Stock Predictions, Articles, and CRISPR Therapeutics AG - Common Shares News

Subscriber Sign in